Article

Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with Sotorasib

2025-10-15

Abstract excerpt

<title>Abstract</title> <p> <italic> <bold>Aims</bold> </italic> : in the genomic era, the advent of next generation sequencing (NGS) technologies has rapidly transformed the clinical paradigm of NSCLC patients who could benefit from a wide series of clinically approved biomarker drive therapies. Among them, <italic>KRAS</italic> p.G12C hotspot mutation became part of the mandatory testing gene panel by ele...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b88a3fde-7e8f-5ac5-a4d9-e147ce142799
DOI: 10.21203/rs.3.rs-7860201/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with SotorasibDOI 10.21203/rs.3.rs-7860201/v1Read

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.Semantic proximity Read

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential.Semantic proximity Read

Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance predictionSemantic proximity Read

Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patientsSemantic proximity Read

Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomasSemantic proximity Read

Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer TypeSemantic proximity Read

Evolution of resistance to KRASG12C inhibitor in a non-small cell lung cancer responderSemantic proximity Read

Evolution of resistance to KRAS <sup>G12C</sup> inhibitor in a non-small cell lung cancer responderSemantic proximity Read

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.Semantic proximity Read

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancerSemantic proximity Read

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.Semantic proximity Read

Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations.Semantic proximity Read